---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-274438"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:05:58.626725+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio announces public offering and $505M debt restructuring with Nant Capital

## Summary
- Proposed public offering of common stock; Jefferies & Piper Sandler lead; 30-day option for 15% additional shares.
- Contingent on offering, Nant Capital converts $230M notes into ~116.5M shares; remaining $505M note due 2027 at SOFR+8%.
- Enters Limited Consent and Amendment to Revenue Interest Purchase Agreement with Oberland consenting to restructuring.
- Shareholder derivative action filed Nov 20, 2024 in Delaware Chancery challenging Sept 2023 financing with Dr. Soon-Shiong.
- Net proceeds to fund ANKTIVA commercialization, BCG-naïve NMIBC and NSCLC trials, and working capital.

## SEC filing metadata
- accession: 0001193125-24-274438
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000119312524274438/0001193125-24-274438-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000119312524274438/d883742d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-274438
- JSON: https://secwatch.observer/filing/0001193125-24-274438.json
- Plain text: https://secwatch.observer/filing/0001193125-24-274438.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.